
CorMedix Investor Relations Material
Latest events

Q1 2025
CorMedix
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CorMedix Inc
Access all reports
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infections and other complications associated with the use of catheters in dialysis and other medical settings. The company's lead product, Defencath, is an anti-infective solution designed to reduce the risk of catheter-related bloodstream infections. CorMedix is dedicated to addressing unmet medical needs in infection prevention and enhancing patient care. The company is headquartered in Berkeley Heights, New Jersey, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CRMD
Country
🇺🇸 United States